Improving risk assessment for pancreatic cancer using genetic information
Multifactor risk scores with susceptibility gene mutations to enhance risk assessment of pancreatic cancer
['FUNDING_R01'] · MAYO CLINIC ROCHESTER · NIH-10931357
This study is looking to create a new way to figure out who might be at higher risk for pancreatic cancer by using genetic information, especially for family members of people who have had the disease, so they can get more personalized care and possibly catch any issues earlier.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MAYO CLINIC ROCHESTER (nih funded) |
| Locations | 1 site (ROCHESTER, UNITED STATES) |
| Trial ID | NIH-10931357 on ClinicalTrials.gov |
What this research studies
This research aims to enhance the assessment of pancreatic ductal adenocarcinoma (PDAC) risk by developing a new multifactor risk score that incorporates genetic mutations associated with hereditary cancer syndromes. By analyzing large datasets from the Mayo Clinic and the UK Biobank, the study will evaluate how these genetic factors can better identify individuals at moderate to high risk for PDAC. The approach includes using whole exome sequencing data to refine risk stratification, particularly for first-degree relatives of PDAC patients. This could lead to more personalized risk assessments and potentially earlier interventions for those at risk.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with a family history of pancreatic cancer, particularly first-degree relatives of affected patients.
Not a fit: Patients without a family history of pancreatic cancer or those not carrying hereditary cancer syndrome mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved early detection and prevention strategies for pancreatic cancer, ultimately saving lives.
How similar studies have performed: Other research has shown promise in using genetic information to enhance cancer risk assessment, indicating that this approach could be effective.
Where this research is happening
ROCHESTER, UNITED STATES
- MAYO CLINIC ROCHESTER — ROCHESTER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: OBERG, ANN LAURA — MAYO CLINIC ROCHESTER
- Study coordinator: OBERG, ANN LAURA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Cause, Cancer Etiology, Cancer Genes, Cancer-Promoting Gene, Cancers